PVMCV
FATE icon

Polaris Venture Management Co V’s Fate Therapeutics FATE Stock Holding History

Polaris Venture Management Co V’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-569,889
Closed -$49.5M – 7
2021
Q2 		$49.5M Hold
569,889
– – 79.24% 1
2021
Q1 		$47M Hold
569,889
– – 60.92% 1
2020
Q4 		$51.8M Sell
569,889
-284,947
-33% -$17.7M 67.63% 1
2020
Q3 		$34.2M Sell
854,836
-284,947
-25% -$9.95M 56.34% 1
2020
Q2 		$39.1M Hold
1,139,783
– – 30.44% 2
2020
Q1 		$25.3M Hold
1,139,783
– – 22.91% 2
2019
Q4 		$22.3M Hold
1,139,783
– – 16.22% 2
2019
Q3 		$17.7M Sell
1,139,783
-333,403
-23% -$6.39M 10.06% 3
2019
Q2 		$29.9M Hold
1,473,186
– – 23.49% 2
2019
Q1 		$25.9M Sell
1,473,186
-350,000
-19% -$5.52M 21.9% 2
2018
Q4 		$23.4M Sell
1,823,186
-650,000
-26% -$9.06M 24.97% 2
2018
Q3 		$40.3M Hold
2,473,186
– – 20.17% 2
2018
Q2 		$28M Hold
2,473,186
– – 15.28% 2
2018
Q1 		$24.1M Hold
2,473,186
– – 13.76% 4
2017
Q4 		$15.1M Hold
2,473,186
– – 13.32% 4
2017
Q3 		$9.79M Hold
2,473,186
– – 8.42% 3
2017
Q2 		$8.01M Hold
2,473,186
– – 8.29% 5
2017
Q1 		$11.3M Hold
2,473,186
– – 12.05% 4
2016
Q4 		$6.21M Hold
2,473,186
– – 7.37% 6
2016
Q3 		$7.72M Hold
2,473,186
– – 8.15% 5
2016
Q2 		$4.2M Hold
2,473,186
– – 4.51% 9
2016
Q1 		$4.45M Hold
2,473,186
– – 4.25% 8
2015
Q4 		$8.34M Hold
2,473,186
– – 6.55% 8
2015
Q3 		$13.2M Hold
2,473,186
– – 8.98% 7
2015
Q2 		$16M Hold
2,473,186
– – 7.14% 7
2015
Q1 		$12.1M Hold
2,473,186
– – 5.4% 6
2014
Q4 		$12.4M Hold
2,473,186
– – 9.84% 5
2014
Q3 		$12.6M Hold
2,473,186
– – 9.73% 6
2014
Q2 		$15.6M Hold
2,473,186
– – 12.72% 5
2014
Q1 		$24.1M Buy
+2,473,186
New +$19.1M 20.01% 4

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polaris Venture Management Co V's FATE Position: Q3 2021 in Review

Polaris Venture Management Co V sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 569,889 shares — an estimated $49.5M sold.

Polaris Venture Management Co V first reported a position in FATE in Q1 2014 and held it in 30 quarters. The position peaked at $51.8M in Q4 2020. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Polaris Venture Management Co V reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Polaris Venture Management Co V sold 569,889 Fate Therapeutics shares in Q3 2021, an estimated $49.5M.
  • Polaris Venture Management Co V first reported a position in Fate Therapeutics in Q1 2014 and held it in 30 quarters.
  • Polaris Venture Management Co V's Fate Therapeutics position peaked at $51.8M in Q4 2020.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Polaris Venture Management Co V's 13F filing for Q3 2021, filed 12 Nov 2021.